A Study of LY573636-sodium in Patients With Metastatic Breast Cancer

• Status: Completed
• Trial end date: 2011-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary purpose of this study is to determine the objective response rate (complete and partial response) for patients who receive LY573636-sodium for metastatic breast cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company

Criteria

Inclusion Criteria:

• Received at least 2 or more prior chemotherapy regimens for metastatic breast cancer.

• Have discontinued all previous therapies for cancer, including chemotherapy, radiotherapy, cancer-related hormonal therapy, or other investigational therapy for at least 4 weeks. Patients who have received whole-brain radiation must wait 90 days.

Exclusion Criteria:

• Serious pre-existing medical condition.

• Have active central nervous system or leptomeningeal metastasis.

• Current hematologic malignancies, acute or chronic leukemia.

• Receiving Warfarin (Coumadin).

• Have a history of radiation therapy involving more than 25% of the bone marrow.